Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia

Sajad Khazal; Partow Kebriaei

doi:10.1016/j.clml.2020.06.011

Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia

Sajad Khazal, Partow Kebriaei

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Despite high complete remission (CR) rates, relapse remains a significant problem among subsets of patients with B acute lymphoblastic leukemia (ALL), and is associated with poor prognosis. The recent Food and Drug Administration approval of highly effective immunotherapies for B-lineage ALL (B-ALL), blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, a chimeric antigen receptor (CAR) modified T-cell therapy, targeting CD19, or CD22, have dramatically changed the therapeutic landscape for the treatment of B-ALL, resulting in high rates of deep and durable remissions. Therefore, there is now debate regarding the role of allogeneic hematopoietic cell transplantation (HCT) in this new landscape. Herein, we review these novel agents, and discuss the sequence of therapy, including allogeneic HCT in B-ALL.

Original language	English (US)
Pages (from-to)	713-719
Number of pages	7
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
Issue number	11
DOIs	https://doi.org/10.1016/j.clml.2020.06.011
State	Published - Nov 2020

Keywords

Blinatumomab
CAR-T cell
Hematopoietic cell transplantation
Immunotherapy
Inotuzumab

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2020.06.011

Cite this

@article{9fb45e0c68484d9095f38aa6d16e0a87,

title = "Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia",

abstract = "Despite high complete remission (CR) rates, relapse remains a significant problem among subsets of patients with B acute lymphoblastic leukemia (ALL), and is associated with poor prognosis. The recent Food and Drug Administration approval of highly effective immunotherapies for B-lineage ALL (B-ALL), blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, a chimeric antigen receptor (CAR) modified T-cell therapy, targeting CD19, or CD22, have dramatically changed the therapeutic landscape for the treatment of B-ALL, resulting in high rates of deep and durable remissions. Therefore, there is now debate regarding the role of allogeneic hematopoietic cell transplantation (HCT) in this new landscape. Herein, we review these novel agents, and discuss the sequence of therapy, including allogeneic HCT in B-ALL.",

keywords = "Blinatumomab, CAR-T cell, Hematopoietic cell transplantation, Immunotherapy, Inotuzumab",

author = "Sajad Khazal and Partow Kebriaei",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = nov,

doi = "10.1016/j.clml.2020.06.011",

language = "English (US)",

volume = "20",

pages = "713--719",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "11",

}

TY - JOUR

T1 - Debate

T2 - Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia

AU - Khazal, Sajad

AU - Kebriaei, Partow

PY - 2020/11

Y1 - 2020/11

N2 - Despite high complete remission (CR) rates, relapse remains a significant problem among subsets of patients with B acute lymphoblastic leukemia (ALL), and is associated with poor prognosis. The recent Food and Drug Administration approval of highly effective immunotherapies for B-lineage ALL (B-ALL), blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, a chimeric antigen receptor (CAR) modified T-cell therapy, targeting CD19, or CD22, have dramatically changed the therapeutic landscape for the treatment of B-ALL, resulting in high rates of deep and durable remissions. Therefore, there is now debate regarding the role of allogeneic hematopoietic cell transplantation (HCT) in this new landscape. Herein, we review these novel agents, and discuss the sequence of therapy, including allogeneic HCT in B-ALL.

AB - Despite high complete remission (CR) rates, relapse remains a significant problem among subsets of patients with B acute lymphoblastic leukemia (ALL), and is associated with poor prognosis. The recent Food and Drug Administration approval of highly effective immunotherapies for B-lineage ALL (B-ALL), blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, a chimeric antigen receptor (CAR) modified T-cell therapy, targeting CD19, or CD22, have dramatically changed the therapeutic landscape for the treatment of B-ALL, resulting in high rates of deep and durable remissions. Therefore, there is now debate regarding the role of allogeneic hematopoietic cell transplantation (HCT) in this new landscape. Herein, we review these novel agents, and discuss the sequence of therapy, including allogeneic HCT in B-ALL.

KW - Blinatumomab

KW - CAR-T cell

KW - Hematopoietic cell transplantation

KW - Immunotherapy

KW - Inotuzumab

UR - http://www.scopus.com/inward/record.url?scp=85088039132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088039132&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2020.06.011

DO - 10.1016/j.clml.2020.06.011

M3 - Review article

C2 - 32694050

AN - SCOPUS:85088039132

SN - 2152-2650

VL - 20

SP - 713

EP - 719

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 11

ER -

Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this